Lidija Marusic

Collagen fibers produced using our patented dry-spinning technology recapitulate the biomechanical and biochemical properties of natural collagen structures. With a fully automated manufacturing system, we are the first to produce collagen fibers at commercial scales for a variety of tissue engineering applications, including additives for 3D bioprinting and hydrogels, and cellular scaffolds for 2D and 3D cell and tissue culture.

Oneka develops and commercializes autonomous desalination systems that use the power of the waves to make fresh water. After seven generations of systems, we have demonstrated the functioning and performance of the technology. A demonstrator is currently installed and producing fresh water at our test facility of the shore of Port Saint-Lucie, Florida. Join the subscription list on our website or add us on LinkedIn to stay tuned.

Invest Nova Scotia is the business development agency of Nova Scotia, Canada. We work to promote economic growth and community economic development in the province, supporting businesses small and large, new and new to Nova Scotia. Please see the government of Nova Scotia terms of use: http://novascotia.ca/terms/

Emagix is developing generative-AI that addresses a key problem in eye care – the inability of routine eye exams to detect early changes in the function of the eye's blood vessels. This inability leads to delayed diagnosis of eye diseases and puts 500M at risk of vision loss. Emagix’s AI enhances the images eye care professionals routinely capture today, transforming them from static structural data into dynamic functional information that is imperative for early disease detection.

Audioptics Medical is a product development and medical imaging technology company. We aim to advance the state of hearing diagnostics, providing diagnostic precision and certainty to the otolaryngological community. The needs of our clinical users and their patients are at the very core of our endeavours. We are customer-focused and have unwavering commitment to quality in engineering, both of which form the foundation of our ability to deliver innovative solutions to our customers.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

At Spring Loaded, weve developed the worlds first bracing solution that addresses patellofemoral pain and multi-compartment osteoarthritis. Our Spring Loaded technology absorbs the pressure from the painful joint during knee flexion and transfers those forces to the back of the leg during extension. Immediate relief that is changing OA bracing and improving patient outcomes.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

At Densitas® we provide artificial intelligence solutions for breast cancer screening, focused on quality, safety, efficiency, and precision breast health. Our solutions present clinical care teams with on-demand actionable information and digitized workflows to systematically improve mammography quality, organizational and workflow efficiencies, and evidence-based decision making. 𝗕𝗲𝘁𝘁𝗲𝗿, 𝗙𝗮𝘀𝘁𝗲𝗿, 𝗦𝗺𝗮𝗿𝘁𝗲𝗿 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲-𝗕𝗮𝘀𝗲𝗱 𝗖𝗮𝗿𝗲 𝙊𝙥𝙩𝙞𝙢𝙞𝙯𝙚 𝙍𝙚𝙛𝙚𝙧𝙧𝙖𝙡𝙨 Quickly identify higher-risk women who may benefit from supplemental imaging with automated breast density and breast cancer risk assessments. 𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙖𝙣𝙙 𝙊𝙥𝙚𝙧𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝘿𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙎𝙪𝙥𝙥𝙤𝙧𝙩 Advanced analytics enable benchmarking, monitoring, and trend-detection with on-demand report generation to facilitate simple performance tracking on an individual and organizational level. 𝙈𝙌𝙎𝘼 𝙀𝙌𝙐𝙄𝙋 𝙖𝙣𝙙 𝘼𝘾𝙍 𝘾𝙤𝙢𝙥𝙡𝙞𝙖𝙣𝙘𝙚 Simplify FDA MQSA EQUIP compliance and ACR Accreditation processes with automated reporting and extensive study filtering and sorting capabilities. 𝙄𝙣𝙛𝙤𝙧𝙢𝙖𝙩𝙞𝙤𝙣 𝙖𝙩 𝙋𝙤𝙞𝙣𝙩-𝙤𝙛-𝘾𝙖𝙧𝙚 Point-of-care quality feedback for technologists to significantly reduce technical recalls, while automated breast density and breast cancer risk assessments provide reliably reproducible results that improve clinical confidence. 𝙋𝙤𝙨𝙞𝙩𝙞𝙤𝙣𝙞𝙣𝙜 𝙋𝙧𝙤𝙛𝙞𝙘𝙞𝙚𝙣𝙘𝙮 Identify strengths and weaknesses in technologists' positioning techniques using advanced analytics and support continuous improvement with Mammography Educators' training materials embedded at point-of-care and on-demand.

Founded in 2012, we are focused on researching, developing, and commercializing breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. With our multi-disciplinary experience in engineering, material science, oncology, medical science, regulatory, finance, business development, sales, marketing, and clinical study coordination we are staffed with the talent to drive the next level of technology for personalized healthcare in oncology.

DeNovaMed Inc. is a pharmaceuticals company based out of 5980 University Ave, Halifax, NS, Canada.

DeNovaMed we specializes in developing groundbreaking antibiotics to combat the toughest bacterial infections and diabetic foot ulcers. Our expertise in microbiology and drug design propels us beyond traditional treatments, delivering novel therapies that promise a healthier future. At DeNovaMed, innovation is the heart of our operations. Our state-of-the-art computer-aided drug design capabilities have yielded multiple classes of antibacterial compounds. These are not only drug-like in their efficacy but are distinctively structured to deter the development of future resistance. Our preclinical candidate, DNM0547, is a testament to our commitment to underappreciated medical needs. This compound shows great potential as a topical treatment for DFU—a complication of diabetes that is much more common than most people think: 35 - 50 million DFUs/yr globally! Meanwhile, DNM0904, an ACP synthase (AcpS) inhibitor with systemic administration potential, is being tested widely to establish its utility in a variety of infectious diseases, including against multi-drug-resistant Gram-positive infections.

EastMed Inc. is a medical manufacturing company dedicated to inventing and bringing to market medical innovations that cater specifically to women's health.

Ardea Outcomes is a small, boutique CRO focused on patient-centric outcomes research and Goal Attainment Scaling (GAS), an area of expertise for our group for over twenty years. Our methods and digital products have been honed over 20+ years to ensure clinically meaningful evidence generation; from phase 1b through to post-market patient support programs, we translate the patient voice into actionable evidence, moving from “what’s the matter” to “what matters most” for patients and caregivers in clinical research and care. Our multidisciplinary team of experts in outcomes measurement, health informatics, data science, and goal attainment scaling make us the research partner of choice for sponsors committed to a truly patient-centric approach.

Collagen fibers produced using our patented dry-spinning technology recapitulate the biomechanical and biochemical properties of natural collagen structures. With a fully automated manufacturing system, we are the first to produce collagen fibers at commercial scales for a variety of tissue engineering applications, including additives for 3D bioprinting and hydrogels, and cellular scaffolds for 2D and 3D cell and tissue culture.

Oneka develops and commercializes autonomous desalination systems that use the power of the waves to make fresh water. After seven generations of systems, we have demonstrated the functioning and performance of the technology. A demonstrator is currently installed and producing fresh water at our test facility of the shore of Port Saint-Lucie, Florida. Join the subscription list on our website or add us on LinkedIn to stay tuned.

Invest Nova Scotia is the business development agency of Nova Scotia, Canada. We work to promote economic growth and community economic development in the province, supporting businesses small and large, new and new to Nova Scotia. Please see the government of Nova Scotia terms of use: http://novascotia.ca/terms/

Innovacorp is Nova Scotia’s early stage venture capital organization. We work to find, fund and foster innovative Nova Scotia start-ups that strive to change the world. Early stage investment is at the core of our business model. We also give entrepreneurs access to world-class incubation facilities, expert advice and other support to help them accelerate their companies. Learn more at www.innovacorp.ca

Emagix is developing generative-AI that addresses a key problem in eye care – the inability of routine eye exams to detect early changes in the function of the eye's blood vessels. This inability leads to delayed diagnosis of eye diseases and puts 500M at risk of vision loss. Emagix’s AI enhances the images eye care professionals routinely capture today, transforming them from static structural data into dynamic functional information that is imperative for early disease detection.